3
Announcements
Trials
Browse
Landscape
Status
Completed
3
Unknown
1
Terminated
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
47
Carcinoma, Hepatocellular
9
Triple Negative Breast Neoplasms
7
Stomach Neoplasms
6
Inflammatory Breast Neoplasms
6
Lymphoma, Large B-Cell, Diffuse
4
Urinary Bladder Neoplasms
3
Non-Muscle Invasive Bladder Neoplasms
3
Esophageal Neoplasms
3
Recurrence
2
Lymphoma
2
Breast Neoplasms, Male
2
Breast Diseases
2
Upper Tract Urothelial Carcinoma
1
Thymoma
1
Small Cell Lung Cancer Extensive Stage
1
Sarcoma
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Postoperative Complications
1
Pancreatic Neoplasms
1
Oesophagogastric Cancer
1
Neoplastic Cells, Circulating
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell
1
Lung Neoplasms
1
Liver Neoplasms
1
Leiomyosarcoma
1
Interventions
Gemcitabine
78
Fluorouracil
27
Oxaliplatin
24
130-nm albumin-bound paclitaxel
24
Leucovorin
18
Capecitabine
15
Albumin-Bound Paclitaxel
15
S 1 (combination)
14
Taxes
12
Irinotecan
11
pembrolizumab
9
folfirinox
9
Radiosurgery
9
Radiotherapy
7
Drug Therapy
7
Cisplatin
7
irinotecan sucrosofate
6
Pancreaticoduodenectomy
5
Paclitaxel
5
Injections
5
Docetaxel
5
Blood Specimen Collection
5
apatinib
4
Radiofrequency Ablation
4
Radiation
4
Biopsy
4
tislelizumab
3
rubitecan
3
nimotuzumab
3
camrelizumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Pancreatic Neoplasms
×
Epirubicin
×
Clear all
NCT03668418
2018-09-12
xenoZ
University of Pisa
Unknown
120 enrolled